17:33 , Jan 11, 2019 |  BC Week In Review  |  Company News

bluebird's five-year pricing model for LentiGlobin could resonate with payers

A potential outcomes-based pricing scheme from bluebird bio Inc. (NASDAQ:BLUE) for its gene therapy could resonate with payers and proffer tentative solutions for navigating challenges around outcome tracking, patient portability and the Medicaid best price...
01:06 , Jan 9, 2019 |  BC Extra  |  Company News

bluebird's five-year pricing model for LentiGlobin could resonate with payers

A potential outcomes-based pricing scheme from bluebird bio Inc. (NASDAQ:BLUE) for its gene therapy could resonate with payers and proffer tentative solutions for navigating challenges around outcome tracking, patient portability and the Medicaid best price...
18:12 , Aug 7, 2018 |  BC Extra  |  Company News

Icahn urges Cigna shareholders to oppose Express Scripts deal

Activist investor Carl Icahn sent a letter Tuesday urging shareholders of Cigna Corp. (NYSE:CI) to vote down its proposed acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). Affiliates of Icahn own about 0.56% of Cigna's outstanding...
21:44 , Mar 23, 2018 |  BioCentury  |  Strategy

Arbiter of value

The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. As an independent, non-governmental body, ICER does not have the authority over reimbursement decisions accorded...
01:01 , Jan 31, 2018 |  BC Extra  |  Company News

Amazon, Berkshire, JPM healthcare deal rocks incumbents

Leading managed care organizations (MCOs), drug distributors and retailers lost more than $32 billion combined in market cap Tuesday on the news that Amazon.com Inc. (NASDAQ:AMZN), Berkshire Hathaway Inc. (NYSE:BRK-A; NYSE:BRK-B) and JPMorgan Chase &...
22:41 , Dec 4, 2017 |  BC Extra  |  Company News

Value-based models a driver of CVS-Aetna deal

The healthcare system's transition toward more value-based payment systems was a driver of the proposed $69 billion acquisition of Aetna Inc. (NYSE:AET) by CVS Health Corp (NYSE:CVS). On Sunday, CVS proposed to acquire Aetna for...
20:45 , Nov 10, 2017 |  BC Week In Review  |  Company News

Anthem updates Yescarta, Exondys 51 coverage

Anthem Inc. (NYSE:ANTM) said it will cover newly approved chimeric antigen receptor (CAR) T therapy Yescarta axicabtagene ciloleucel (KTE-C19) from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) for certain patients. The firm...
23:13 , Nov 9, 2017 |  BC Extra  |  Company News

Anthem updates Yescarta, Exondys 51 coverage

Anthem Inc. (NYSE:ANTM) said it will cover newly approved chimeric antigen receptor (CAR) T therapy Yescarta axicabtagene ciloleucel (KTE-C19) from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) for certain patients. The firm...
23:40 , Nov 6, 2017 |  BC Extra  |  Company News

Management tracks: Anthem, Aimmune

Anthem Inc. (NYSE:ANTM) said President and CEO Joseph Swedish will step down, effective Nov. 17. He will continue to serve as executive chairman until May 2018 and as senior adviser through May 2020. He is...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Boehringer and Anthem begin real-world COPD trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Anthem Inc. (NYSE:ANTM) with its outcomes research subsidiary HealthCore Inc. have begun enrolling patients in a real-world study evaluating the effect of Stiolto Respimat tiotropium/olodaterol on the occurrence of...